E-Mail
COLUMBUS, Ohio - A new study of advanced small-cell lung cancer (SCLC) led by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC - James) has identified molecular patterns linked to patients developing resistance to certain therapies.
This study, published in the journal
JTO Clinical and Research Reports, examined more than 60 tumors from five patients. OSUCCC - James researchers identified distinct mutational and molecular changes in four SCLC subtypes. The findings provide new insights into the patterns treatment resistance and could offer new targets for the development of more effective immunotherapy and other therapies for advanced SCLC, which progresses quickly and is usually fatal.
E-Mail
The results of a large, retrospective study of patients who received a form of immunotherapy for non-small cell lung cancer (NSCLC) revealed that patients may get more than one immune-related side effect, and identified a correlation between these multisystem immune-related adverse events (irAEs) and improved patient survival. In fact, patients who developed two irAEs did better, in terms of delaying the time to cancer progression and overall survival, than those who developed only one irAE. According to the researchers, this new information will be helpful in discussing with patients the spectrum of immune side effects that may occur from immunotherapy and the implications for their survival.